Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab.

Autor: Jasper S; Abteilung für Dermatologie, Zentrum für Dermatoonkologie, Universitätsklinikum Tübingen., Keim U; Abteilung für Dermatologie, Zentrum für Dermatoonkologie, Universitätsklinikum Tübingen., Leiter U; Abteilung für Dermatologie, Zentrum für Dermatoonkologie, Universitätsklinikum Tübingen., Amaral T; Abteilung für Dermatologie, Zentrum für Dermatoonkologie, Universitätsklinikum Tübingen., Flatz L; Abteilung für Dermatologie, Zentrum für Dermatoonkologie, Universitätsklinikum Tübingen., Forschner A; Abteilung für Dermatologie, Zentrum für Dermatoonkologie, Universitätsklinikum Tübingen.

Publikováno v: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG [J Dtsch Dermatol Ges] 2023 Oct; Vol. 21 (10), pp. 1137-1147.

90P Long-term outcomes in melanoma patients achieving a complete response under immune checkpoint inhibition

Autor: Chatziioannou, E., Leiter-Stoppke, U., Thomas, I., Keim, U., Forschner, A., Flatz, L., Amaral, T.M.S.

Publikováno v: In Immuno-Oncology and Technology December 2022 16 Supplement 1

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.

Autor: Chatziioannou E; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Tübingen, Germany., Roßner J; Department of Dermatology, University of Heidelberg, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany., Aung TN; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA., Niessner H; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Tübingen, Germany., Keim U; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany., Serna-Higuita LM; Department of Clinical Epidemiology and Applied Biostatistics, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany., Bonzheim I; Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany., Kuhn Cuellar L; Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany., Westphal D; Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Technical University Dresden, 01307 Dresden, Germany., Steininger J; Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Technical University Dresden, 01307 Dresden, Germany., Meier F; Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Technical University Dresden, 01307 Dresden, Germany., Pop OT; Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Forchhammer S; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany., Flatz L; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Eigentler T; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany., Garbe C; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany., Röcken M; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Tübingen, Germany., Amaral T; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Tübingen, Germany., Sinnberg T; Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Tübingen, Germany; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. Electronic address: tobias.sinnberg@med.uni-tuebingen.de.

Publikováno v: EBioMedicine [EBioMedicine] 2023 Jul; Vol. 93, pp. 104644. Date of Electronic Publication: 2023 Jun 07.

Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland.

Autor: Keim U; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Katalinic A; Institute of Clinical Epidemiology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany., Holleczek B; Saarland Cancer Registry, Saarbrücken, Germany., Wakkee M; Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands., Garbe C; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Leiter U; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. Electronic address: ulrike.leiter@med.uni-tuebingen.de.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Apr; Vol. 183, pp. 60-68. Date of Electronic Publication: 2023 Jan 28.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.